Inadequate long-chain omega-3 fatty acid status has a substantial impact on our health. Human RCT, observational, in vitro and in vivo animal studies all demonstrate that omega-3 fats from fish improve inflammatory regulation and its associated conditions. Yet, due to inconsistency in findings, the validity of omega-3 fatty acids as ‘treatments’ has been brought into question in the reporting of studies. To date, few studies have monitored the correlation between omega-3 dose, subsequent cellular enrichment of these fatty acids and clinical outcomes.
In this webinar, Dr Bailey presents the latest evidence for the importance of a biomarker-based, personalised approach to omega-3 treatment – one that significantly improves consistency in clinical outcomes and offers an antidote to the ‘one-size fits all’ approach that is responsible for significant individual variations in response in many published studies.